Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MDGL |
---|---|---|
09:32 ET | 2063 | 220.595 |
09:34 ET | 100 | 219.9 |
09:39 ET | 100 | 222.84 |
09:41 ET | 300 | 220.29 |
09:43 ET | 600 | 219.99 |
09:45 ET | 300 | 219.84 |
09:52 ET | 300 | 220.455 |
09:54 ET | 200 | 221.64 |
09:56 ET | 529 | 221.72 |
09:59 ET | 1400 | 221.485 |
10:01 ET | 2200 | 221.755 |
10:03 ET | 100 | 221.775 |
10:12 ET | 200 | 222.155 |
10:14 ET | 100 | 221.86 |
10:17 ET | 271 | 221.06 |
10:19 ET | 205 | 220.86 |
10:21 ET | 650 | 220.2 |
10:24 ET | 1905 | 219.935 |
10:26 ET | 601 | 220.495 |
10:28 ET | 160 | 221.105 |
10:32 ET | 209 | 220.7 |
10:33 ET | 1030 | 220.46 |
10:35 ET | 499 | 221.45 |
10:37 ET | 1700 | 221.99 |
10:39 ET | 160 | 222.0407 |
10:42 ET | 150 | 221.665 |
10:46 ET | 600 | 222.385 |
10:48 ET | 200 | 222.61 |
10:50 ET | 100 | 222.965 |
10:53 ET | 100 | 223.63 |
11:00 ET | 300 | 223.5 |
11:02 ET | 125 | 224.5523 |
11:09 ET | 100 | 223 |
11:20 ET | 200 | 223.09 |
11:22 ET | 600 | 222.93 |
11:24 ET | 200 | 222.7 |
11:26 ET | 100 | 222.775 |
11:27 ET | 472 | 223.28 |
11:29 ET | 1200 | 223 |
11:31 ET | 100 | 222.85 |
11:36 ET | 100 | 222.61 |
11:44 ET | 200 | 222.81 |
11:45 ET | 109 | 222.755 |
11:47 ET | 200 | 222.15 |
11:49 ET | 200 | 221.79 |
11:56 ET | 100 | 221.55 |
11:58 ET | 100 | 221.6 |
12:00 ET | 200 | 221.425 |
12:02 ET | 200 | 221.165 |
12:03 ET | 5849 | 222.99 |
12:09 ET | 100 | 222.92 |
12:12 ET | 100 | 222.61 |
12:20 ET | 900 | 222.2006 |
12:23 ET | 300 | 221.9 |
12:25 ET | 300 | 221.935 |
12:27 ET | 9300 | 221.81 |
12:30 ET | 300 | 222.92 |
12:32 ET | 100 | 222.805 |
12:36 ET | 300 | 222.34 |
12:39 ET | 200 | 221.89 |
12:43 ET | 620 | 222.35 |
12:50 ET | 475 | 221.8091 |
12:57 ET | 300 | 222.76 |
12:59 ET | 500 | 222.6 |
01:01 ET | 500 | 222.25 |
01:06 ET | 400 | 221.38 |
01:08 ET | 500 | 221.17 |
01:10 ET | 300 | 220.51 |
01:14 ET | 100 | 220.385 |
01:17 ET | 1100 | 220.345 |
01:19 ET | 5024 | 220.43 |
01:21 ET | 200 | 220.53 |
01:24 ET | 400 | 220.66 |
01:26 ET | 100 | 220.32 |
01:28 ET | 100 | 220.41 |
01:30 ET | 100 | 220.45 |
01:32 ET | 100 | 220.415 |
01:35 ET | 300 | 220.11 |
01:37 ET | 300 | 220.04 |
01:42 ET | 200 | 220.05 |
01:44 ET | 25300 | 220.64 |
01:46 ET | 200 | 220.89 |
01:48 ET | 221 | 220.52 |
01:53 ET | 200 | 220.61 |
01:55 ET | 200 | 220.49 |
01:57 ET | 100 | 219.9975 |
02:00 ET | 500 | 220.63 |
02:09 ET | 341 | 220.3892 |
02:11 ET | 500 | 220.705 |
02:13 ET | 200 | 220.79 |
02:15 ET | 100 | 220.86 |
02:18 ET | 300 | 220.85 |
02:22 ET | 100 | 220.5 |
02:24 ET | 200 | 220.32 |
02:26 ET | 205 | 220.08 |
02:27 ET | 200 | 220.09 |
02:29 ET | 700 | 219.9675 |
02:31 ET | 404 | 220.52 |
02:40 ET | 957 | 220.81 |
02:42 ET | 200 | 221.11 |
02:44 ET | 100 | 220.995 |
02:45 ET | 100 | 220.68 |
02:47 ET | 100 | 220.71 |
02:51 ET | 100 | 220.57 |
02:54 ET | 200 | 220.26 |
02:56 ET | 100 | 220.36 |
02:58 ET | 500 | 220.31 |
03:00 ET | 273 | 220.47 |
03:02 ET | 1400 | 220.885 |
03:03 ET | 200 | 220.92 |
03:05 ET | 200 | 220.995 |
03:07 ET | 300 | 221.47 |
03:12 ET | 300 | 221.74 |
03:18 ET | 799 | 221.78 |
03:20 ET | 100 | 222.0375 |
03:21 ET | 700 | 222.24 |
03:23 ET | 200 | 222.515 |
03:25 ET | 200 | 222.585 |
03:27 ET | 400 | 222.38 |
03:32 ET | 300 | 222.23 |
03:34 ET | 694 | 222.41 |
03:38 ET | 300 | 222.555 |
03:39 ET | 100 | 222.65 |
03:41 ET | 500 | 222.37 |
03:43 ET | 1617 | 223.2 |
03:45 ET | 100 | 223.45 |
03:48 ET | 400 | 223.4 |
03:50 ET | 2040 | 222.965 |
03:52 ET | 2119 | 222.46 |
03:54 ET | 2577 | 222.435 |
03:56 ET | 2433 | 222.075 |
03:57 ET | 4181 | 222.735 |
03:59 ET | 6329 | 222.51 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Madrigal Pharmaceuticals Inc | 4.7B | -9.6x | --- |
Immunitybio Inc | 4.4B | -6.1x | --- |
Immunovant Inc | 4.3B | -16.2x | --- |
Nuvalent Inc | 4.3B | -27.4x | --- |
BridgeBio Pharma Inc | 5.2B | -8.6x | --- |
Krystal Biotech Inc | 4.5B | 83.1x | --- |
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.7B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 21.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.43 |
EPS | $-23.08 |
Book Value | $20.39 |
P/E Ratio | -9.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.